|
Canada-0-GrocersRetail Azienda Directories
|
Azienda News:
- Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
- Gilead Sciences - Wikipedia
Gilead Sciences Gilead Sciences, Inc ( ˈɡɪliəd ) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir sofosbuvir and sofosbuvir
- Dear Gilead, Stop Being Greedy.
Gilead Sciences is blocking access to a twice-yearly injection (Lenacapavir) that can both treat HIV and prevent new infections Lenacapavir could become a cornerstone in controlling the global HIV epidemic — improving adherence, reducing transmission, and saving lives
- Gilead Sciences, Inc. (GILD) - Yahoo Finance
Gilead Sciences, Inc , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally
- Gilead Sciences Inc. (GILD) Stock Price Today - WSJ
View the latest Gilead Sciences Inc (GILD) stock price, news, historical charts, analyst ratings and financial information from WSJ
- Gilead Sciences - LinkedIn
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people From our pioneering virology medicines to our growing impact in oncology, we're delivering
- Gilead Sciences Inc - Reuters
Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth more than $2 billion to expand its pipeline of immune disorder drugs
- Gilead Sciences Acquires Ouro Medicines for $2. 2 Billion to Lead . . .
In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines for approximately $2 175 billion The deal marks Gilead’s second massive investment in the immunology sector within a single month, following its $7 8 billion acquisition of Arcellx, Inc
- GILD: Gilead Sciences Inc - Stock Price, Quote and News - CNBC
Get Gilead Sciences Inc (GILD:NASDAQ) real-time stock quotes, news, price and financial information from CNBC
- Gilead Sciences Inc (GILD) Stock Price News - Google Finance
Get the latest Gilead Sciences Inc (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions
|
|